
Opinion|Videos|May 21, 2024
Evaluating CDK4/6 Inhibitor Safety Profiles: An Analysis of Adverse Events
A medical expert compares CDK4/6 inhibitors and discusses the importance of monitoring specific parameters, such as ECGs and laboratory tests, to minimize adverse events associated with each drug.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Pharmacists Should Know About High-Dose Semaglutide’s Safety Profile
2
Ensitrelvir Demonstrates Significant COVID-19 Post-Exposure Prophylaxis Efficacy in Phase 3 Trial
3
How Advanced Technology Is Reshaping Medication Safety and Pharmacy Practice
4
Declining Vitamin K Prophylaxis in Newborns: A Growing Threat to Neonatal Safety
5


































































































































